Drug developer MapLight prices US IPO at $17 per share-March 2024-www.financetom.com

Drug developer MapLight prices US IPO at $17 per share

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Drug developer MapLight prices US IPO at $17 per share

Oct 26, 2025 3:00 PM

Oct 26 (Reuters) - MapLight Therapeutics, a

clinical-stage biotech backed by Novo Holdings, said on Sunday

it has priced its U.S. initial public offering at $17 per share.

Previous page： Pakistan's national carrier resorts to flight cancellation owing to non-payment of dues Next page： Mahindra, Volvo among corporations pushing for fossil fuel exit at COP28

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Pakistan's national carrier resorts to flight cancellation owing to non-payment of dues

Oct 23, 2023

The airline, which was once considered the pride of Pakistan and was the first international airline to be given access to fly to Beijing, is said to be suffering millions in losses on a daily basis.

Mahindra, Volvo among corporations pushing for fossil fuel exit at COP28

Oct 23, 2023

Companies are increasingly committing to their own timelines for reducing their emissions, but many acknowledge that their ability to slow planet-warming CO2 emissions is contingent on faster action from governments.

IMF warns Europe against prematurely declaring victory over inflation

Nov 8, 2023

The Washington-based IMF said that cost of underestimating inflation’s persistence could be painfully high and result in another painful round of rate hikes that could rob the economy of a large chunk of growth.

Pfizer’s $43 billion purchase of Seagen gets green light from EU antitrust

Oct 20, 2023

Pfizer announced the deal in March, its largest purchase in a string of recent acquisitions thanks to a once-in-a-lifetime cash windfall from its COVID-19 vaccine and treatment.